Pfizer Inc. (PFE)

Pfizer Inc. stock has experienced fluctuations in the past six months. In early May 2026, shares decreased to $26.00 USD, the lowest since February 2026. Over the four weeks leading up to May 8, 2026, the stock lost 4.91%, but increased by 13.71% in the last 12 months. On March 31, 2026, shares had increased to $28.00 USD, the highest since November 2024. In February 2026, Pfizer's stock fell approximately 5% after releasing mid-stage data for its obesity therapy, which showed weight loss but raised safety concerns. Q4 2025 earnings indicated a projected revenue decline for 2026, partly due to patent cliffs. Q1 2026 revenues were $14.5 billion, a 5% year-over-year increase, and the company reaffirmed its full-year 2026 financial guidance.

Pfizer has acknowledged the expected seasonality of demand for certain products, particularly its COVID-19 franchise, including the Comirnaty vaccine and Paxlovid antiviral treatment, which is expected to be "back-half-weighted" due to higher sales in the fall and winter months. This seasonality can make early adjustments to financial guidance tricky. Pfizer's revenue has shown a clear seasonal pattern across recent quarters, with peaks often observed in the fourth quarter and troughs in the first quarter.

Pfizer Inc. is a leading American multinational pharmaceutical and biotechnology corporation headquartered in New York City, founded in 1849. It operates within the pharmaceutical and biotechnology industries, focusing on the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products globally. The company's portfolio includes medicines and vaccines across various therapeutic areas, such as immunology, oncology, and cardiology. Key products include Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance. Pfizer also offers biosimilars and has a contract manufacturing business. Historically, Pfizer's global portfolio included consumer health care products like Advil and Centrum, though some are now Viatris products.

Pfizer Inc. has a significant global presence, serving approximately 200 countries and territories worldwide. The company's operations are categorized into three regions: the United States, Developed Markets, and Emerging Markets. In the U.S., Pfizer operates 11 manufacturing sites and two distribution centers across nine states. Its global office locations include cities such as Athens, Chennai, and Dublin, among others.

Pfizer's brand reputation saw a significant boost during the COVID-19 pandemic due to its role in developing one of the primary vaccines and booster shots. Its Impression score rose from 8 in January 2019 to 36 in June 2021. However, as emergency restrictions eased, Pfizer's Impression score declined from its pandemic-era highs, reaching 14 by June 3, 2023, still better than pre-pandemic levels. The pharmaceutical industry's reputation among patient groups saw a decline in 2023, but Pfizer was still among the Big Pharma companies with the best reputations according to PatientView.

Pfizer Inc. is a publicly traded company on the New York Stock Exchange (NYSE: PFE), with ownership distributed among numerous shareholders. Institutional investors hold approximately 68% of shares, while retail investors account for about 35%. Insider ownership is minimal, under 0.3%, with CEO Albert Bourla holding the largest individual insider position. The largest institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corporation.